NovaBiotics to Present New Data at 42nd European Cystic Fibrosis Conference
15-Mar-2019
NovaBiotics Awarded £1.8m in Small Business Research Innovation-Innovate UK grant funding to Advance its Antifungal Drug Candidate, Novamycin
18-Feb-2019
NovaBiotics Welcomes the UK Governments Announcement on Tackling Antimicrobial Resistance (AMR)
24-Jan-2019
Grant Support for Lynovex
04-Dec-2018
NovaBiotics Featured in BIA Guide to Antimicrobial Resistance
26-Oct-2018
NovaBiotics at North American Cystic Fibrosis Conference (NACFC), Denver 2018
17-Oct-2018
Data on the mucolytic mechanism of action of Lynovex will be presented at NACFC 2018.
20-Jul-2018
CARE CF 1 Lynovex clinical trial data selected for presentation at NACFC 2018.
20-Jul-2018
Positive Top Line Data from the CARE CF 1 Clinical Study of Oral Lynovex in Cystic Fibrosis Exacerbations
10-Jul-2018
NovaBiotics CEO named as one of the top 30 woman leaders in UK healthcare
14-Jun-2018
Cysteamine, an endogenous aminothiol, and cystamine, the disulfide product of oxidation, increase Pseudomonas aeruginosa sensitivity to reactive oxygen and nitrogen species and potentiate therapeutic antibiotics against bacterial infection.
03-Apr-2018
How Lynovex works to boost antibiotics in combatting Pseudomonas aeruginosa infection in cystic fibrosis
19-Mar-2018
NovaBiotics’ Lynovex receives Fast Track Designation for Cystic Fibrosis Exacerbations
12-Mar-2018
NovaBiotics Chief Executive Officer Elected as a Fellow of the Royal Society of Edinburgh
27-Feb-2018
NovaBiotics and BioPharma Dealmakers’ ‘Fighting Infectious Diseases’ Webcast
22-Feb-2018
NovaBiotics Receives Most Innovative EU Biotech SME 2017 Award
23-Nov-2017
Enrolment reaches 50% in Lynovex CARE-CF-1 trial
02-Nov-2017
NovaBiotics at North American Cystic Fibrosis Conference (NACFC), Indianapolis
30-Oct-2017
Reflections from World AMR Congress
19-Oct-2017
EuropaBio announces the finalists for the Most innovative European Biotech SME Awards 2017
18-Oct-2017
NovaBiotics at World Antimicrobial Resistance Congress, Washington
13-Sep-2017
NovaBiotics at ASM/ESCMID Conference
31-Aug-2017
NovaBiotics at the 7th International Meeting on Antimicrobial Peptides
21-Aug-2017
NovaBiotics Chief Executive responds to Public Health England warning on Candida auris fungus
16-Aug-2017
NovaBiotics featured on STV News
04-Aug-2017
New Drug Kills MRSA – including strains with antibiotic resistance
03-Aug-2017
50th patient recruited for CARE- CF-1 Lynovex clinical study
01-Aug-2017
NovaBiotics’ novel antimicrobial Luminaderm highly effective against Multi drug resistant MRSA
16-Jun-2017
NovaBiotics participating in BIO 2017 in San Diego
15-Jun-2017
NovaBiotics at European Cystic Fibrosis Conference in Seville
06-Jun-2017
NovaBiotics at American Society for Microbiology
26-May-2017
30 subjects now randomised in Lynovex CARE-CF-1 trial
10-May-2017
NovaBiotics contribution to ECCMID 2017
13-Apr-2017
NovaBiotics Quality Management System Achieves ISO 9001 certification
11-Apr-2017
NovaBiotics to host live Twitter Lynovex Q&A
24-Mar-2017
NovaBiotics Chief Executive Addresses 'Superbugs & Superdrugs' Conference on Antimicrobial Drug Discovery
21-Mar-2017
NovaBiotics CEO to speak at 19th Superbugs & Superdrugs Conference
17-Mar-2017
NovaBiotics secures an additional £3.0 million investment from Woodford Investment Management
03-Mar-2017
NovaBiotics CEO to speak at 10th Berlin Conference on Life Sciences
21-Feb-2017
NovaBiotics at ECCMID 2017
25-Jan-2017
NovaBiotics CEO featured as one of 15 women leading in European Biotech
18-Jan-2017
NovaBiotics announces first patients dosed in Lynovex clinical study
16-Jan-2017
Commercial Collaboration Deal for (Oral) Lynovex®
05-Aug-2016
NovaBiotics "one to watch" for 2017
14-Jul-2016
NovaBiotics Announces New Data on Cysteamine (Nylexa™) as an Antimicrobial Resistance Breaker in Multi Drug Resistant Bacteria
18-Jun-2016
NovaBiotics Highlights Importance of Co-ordinated Approach to Antimicrobial Resistance
07-Jun-2016
NovaBiotics Discusses Innovation for Antimicrobial Resistance at BIO
03-Jun-2016
Lynovex Clinical Trial Data Published
12-May-2016
NovaBiotics wins Investment of the Year
05-Feb-2016
Sad news on NovaBiotics' co-founder and first Chairman
10-Sep-2015
Lynovex® Activity in CF sputum & Against the Emerging CF Pathogen, Mycobacterium abscessus
12-Aug-2015
Positive Lynovex Phase IIa data presented at the 38th European Cystic Fibrosis Symposium
12-Jun-2015
NovaBiotics Raises £5.0 million in a Private Placement from Woodford Investment Management
19-Jan-2015
Dr Deborah O’Neil Named EY UK Health Products & Services Entrepreneur of 2014
07-Oct-2014
NovaBiotics Receives Orphan Drug Status from FDA
16-Sep-2014
Initiation of a Phase IIa Clinical Study for Lynovex® in Cystic Fibrosis
25-Jun-2014
NovaBiotics’ Dr Deborah O’Neil Named as an EY Scotland Entrepreneur of 2014
20-Jun-2014
Collaboration between NovaBiotics and the Cystic Fibrosis Trust
31-Jan-2014
NovaBiotics’ Lynovex® Gains Support From The UK’s Cystic Fibrosis Trust
30-Oct-2013
NovaBiotics Enters into Agreement with Taro
24-Aug-2013
Excellent Results From the Unblinding of the Novexatin® Phase IIa Clinical Trial
08-Jul-2010
